📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
56 announcements match the current filters (relevance ≥ 5).
Anlon Healthcare FY26 PAT Rises 41.8% to ₹29.1 Cr; Targets ₹800 Cr Revenue by FY28
Anlon Healthcare delivered a strong FY26 performance with consolidated revenue growing 43% YoY to ₹172.22 crore and PAT increasing 41.8% to ₹29.09 crore. The company has provided aggressive forward-looking guidance, targeting ₹380-400 crore in revenue for FY27 and ₹700-800 crore for FY28, supported by the acquisitions of Apiqo Organics and Bizotic Life Science. Management is initiating a ₹130 crore Capex for standalone expansion, aiming for a 30% revenue CAGR over the next three years while maintaining EBITDA margins in the 24-25% range.
Key Highlights
FY26 consolidated revenue grew 42.98% YoY to ₹172.22 crore with a PAT of ₹29.09 crore.
Management guided for a significant revenue jump to ₹380-400 crore in FY27 and ₹700-800 crore in FY28.
Acquisitions of Apiqo Organics and Bizotic Life Science have expanded total capacity to 1400-1600 MTPA.
A new ₹130 crore Capex project is underway, expected to be operational by Q1 FY28 with a peak revenue potential of ₹450 crore.
The company plans to launch 7 new APIs and file 3-5 additional DMFs in FY27 to deepen regulated market penetration.
👀 What to Watch
Investors should focus on the company's ability to execute its massive capacity expansion and integrate acquisitions, as the ambitious FY28 revenue targets represent a nearly 4x growth from FY26 levels.
Anlon Healthcare Targets 30% Revenue CAGR and Quadruples Capacity via Strategic Acquisitions
Anlon Healthcare (AHCL) has outlined a robust growth trajectory in its FY26 investor presentation, projecting a 30% revenue CAGR over the next three years. The company successfully completed the acquisitions of Bizotic Lifescience and Apiqo Organics for a combined consideration of ₹9.19 crore, boosting total manufacturing capacity to 1,400-1,600 MTPA. Revenue mix has shifted significantly, with Pharmaceutical Intermediates now contributing 71.24% of total revenue compared to 35.70% in the previous year. The company is also diversifying into high-growth circular economy sectors, including e-waste management and lithium-ion battery recycling.
Key Highlights
Acquired majority stakes in Bizotic Lifescience (56.67%) and Apiqo Organics (67.48%) to expand capacity from 400 MTPA to 1,600 MTPA.
Guided for a 30% revenue CAGR over the next 3 years supported by 21 global DMF filings and 65 commercialized products.
Pharmaceutical Intermediates segment revenue share surged to 71.24% in FY26, up from 35.70% in FY25.
Received key regulatory approvals from EDQM (Europe), ANVISA (Brazil), and NMPA (China) for core API products.
Announced strategic entry into battery recycling (Li, Co, Ni, Mn recovery) and e-waste management to diversify the portfolio.
👀 What to Watch
Investors should focus on the company's ability to maintain margins while scaling capacity four-fold and monitor the execution of the new e-waste and battery recycling verticals. The aggressive 30% CAGR guidance suggests a strong growth outlook, provided the integration of recent acquisitions remains seamless.
Anlon Healthcare FY26 Results: Consolidated PAT up 42% to ₹29.09 Cr; Revenue grows 43%
Anlon Healthcare reported a strong financial performance for FY26, with consolidated total income rising 43% YoY to ₹172.22 crore. Profitability saw a significant boost as PAT increased by 41.77% to ₹29.09 crore, while EBITDA grew by 47.55% to ₹47.77 crore. The company successfully integrated acquisitions like Bizotic Lifescience and Apiqo Organics to strengthen its manufacturing and backward integration capabilities. Management has provided a robust outlook, targeting a 30% revenue CAGR over the next three years with EBITDA margins maintained between 25-30%.
Key Highlights
Consolidated Total Income grew 42.98% YoY to ₹172.22 Cr in FY26 compared to ₹120.46 Cr in FY25.
Consolidated PAT increased by 41.77% to ₹29.09 Cr, while EBITDA rose 47.55% to ₹47.77 Cr.
Management issued guidance for 30% revenue CAGR over the next three years with 25-30% EBITDA margins.
Completed the acquisition of Bizotic Lifescience and integrated Apiqo Organics to enhance supply-chain efficiency.
Advancing CDMO business with 3 molecules for global innovators and a total of 21 DMF filings to date.
👀 What to Watch
Investors should consider this a strong growth signal in the API and specialty chemical space, backed by solid margin guidance and strategic acquisitions. Monitor the company's ability to scale its CDMO vertical and maintain the projected 30% CAGR in a competitive global environment.
AHCL FY26 Revenue Jumps 46.7% to ₹176.5 Cr; Annual PAT Grows 35.5% to ₹27.8 Cr
Anlon Healthcare Limited (AHCL) reported a robust performance for the financial year ended March 31, 2026, with annual revenue from operations rising 46.7% YoY to ₹176.50 crore. Annual Profit After Tax (PAT) grew by 35.5% to ₹27.81 crore, despite a year-on-year decline in Q4 profit which stood at ₹9.79 crore compared to ₹16.65 crore in Q4 FY25. The company's balance sheet expanded significantly, with total assets nearly doubling to ₹317.21 crore, supported by an increase in equity share capital to ₹53.15 crore.
Key Highlights
Annual Revenue from Operations increased to ₹176.50 crore in FY26 from ₹120.29 crore in FY25.
Full-year Net Profit (PAT) rose 35.5% to ₹27.81 crore compared to ₹20.52 crore in the previous fiscal.
Quarter-on-quarter revenue growth was strong, with Q4 FY26 revenue at ₹55.42 crore vs ₹35.58 crore in Q3 FY26.
Total Assets grew to ₹317.21 crore from ₹181.30 crore, driven by higher inventories and trade receivables.
Earnings Per Share (EPS) for FY26 stood at ₹5.93 on an expanded equity base of ₹53.15 crore.
👀 What to Watch
Investors should view the strong annual growth and asset expansion as positive indicators of scaling operations. However, the decline in Q4 YoY profitability and the significant increase in trade receivables (₹104.17 crore) warrant closer monitoring of working capital efficiency.
Anlon Healthcare FY26 Revenue Jumps 46.7% to ₹176.5 Cr; PAT Up 35.5% to ₹27.8 Cr
Anlon Healthcare Limited (AHCL) reported a robust financial performance for the fiscal year ended March 31, 2026, with annual revenue from operations growing 46.7% YoY to ₹176.50 crore. Net profit for the full year increased by 35.5% to ₹27.81 crore, up from ₹20.52 crore in FY25. The fourth quarter (Q4 FY26) was particularly strong, with PAT nearly doubling to ₹9.79 crore compared to ₹5.15 crore in the year-ago period. However, annual EPS slightly declined to ₹5.93 from ₹6.37, reflecting equity dilution as the share capital increased from ₹39.85 crore to ₹53.15 crore.
Key Highlights
Annual Revenue from Operations increased by 46.7% YoY to ₹17,649.87 lacs in FY26.
Full-year Profit After Tax (PAT) rose 35.5% to ₹2,780.82 lacs compared to ₹2,051.79 lacs in FY25.
Q4 FY26 PAT surged 90% YoY to ₹979.20 lacs from ₹515.20 lacs in Q4 FY25.
Total Assets grew significantly by 75% to ₹31,720.50 lacs as of March 31, 2026.
Equity Share Capital expanded to ₹5,315.15 lacs from ₹3,985.15 lacs, indicating a capital raise during the fiscal year.
👀 What to Watch
Investors should view the strong top-line and bottom-line growth as a positive sign of operational scaling, though the slight EPS dilution due to increased share capital warrants monitoring for future earnings consistency.
Anlon Healthcare Completes Acquisition of 63.98% Stake in Remember India Health Links
Anlon Healthcare Limited (AHCL) has successfully completed the acquisition of a 63.98% equity stake in Remember India Health Links Private Limited as of May 8, 2026. This transaction follows the Share Purchase Agreement (SPA) previously executed on April 16, 2026. Consequently, Remember India Health Links has now become a subsidiary of AHCL. This move signifies a strategic expansion for the company into new healthcare segments or markets.
Key Highlights
Acquired a controlling 63.98% equity shareholding in Remember India Health Links Private Limited
The target company has officially become a subsidiary of Anlon Healthcare Limited effective May 8, 2026
Completion follows the execution of a Share Purchase Agreement dated April 16, 2026
The acquisition is in compliance with Section 179 of the Companies Act, 2013 and SEBI Listing Regulations
👀 What to Watch
Investors should monitor the upcoming quarterly results to assess the revenue and margin contribution from this new subsidiary. This acquisition indicates a growth-oriented strategy through inorganic expansion.
Anlon Healthcare Allots 26.57 Crore Bonus Shares in 1:1 Ratio
Anlon Healthcare Limited (AHCL) has finalized the allotment of 26,57,57,500 bonus equity shares of Rs. 2 each. The allotment was made in a 1:1 ratio to shareholders who held the stock as of the record date, April 24, 2026. This corporate action has effectively doubled the company's total number of outstanding equity shares to 53,15,15,000. Following this allotment, the paid-up equity share capital of the company has increased to Rs. 106.30 crore.
Key Highlights
Allotted 26,57,57,500 fully paid-up bonus equity shares of face value Rs. 2 each
Bonus issue executed in the proportion of 1:1 for eligible members
Total paid-up equity capital increased from Rs. 53.15 crore to Rs. 106.30 crore
Post-allotment, the total number of equity shares stands at 53,15,15,000
The record date for the bonus eligibility was fixed as April 24, 2026
👀 What to Watch
Investors should observe the increased liquidity in the stock and the proportional adjustment in the share price following the 1:1 bonus issue. No immediate action is required as the total investment value remains unchanged despite the higher share count.
Anlon Healthcare Finalizes 1:5 Stock Split with New ISIN; Record Date April 24, 2026
Anlon Healthcare Limited (AHCL) has received confirmation for its new ISIN (INE0Y8W01025) following the approval of a stock split. The company is subdividing each existing equity share with a face value of Rs. 10 into five equity shares with a face value of Rs. 2 each. This corporate action is scheduled to take effect on the record date of April 24, 2026. Both NSDL and CDSL have activated the new ISIN to facilitate the transition in the depository systems.
Key Highlights
Stock split ratio of 1:5, subdividing Rs. 10 face value shares into Rs. 2 face value shares
Record date for the sub-division is officially set for April 24, 2026
New ISIN INE0Y8W01025 activated by both CDSL and NSDL for post-split trading
The corporate action aims to enhance liquidity and make shares more accessible to retail investors
👀 What to Watch
Existing shareholders do not need to take any action as the additional shares will be credited automatically post-record date. Investors should expect the stock price to adjust downward by a factor of five on the ex-split date to reflect the new face value.
Anlon Healthcare to Acquire 63.98% Stake in Remember India Health Links for ₹5.38 Crore
Anlon Healthcare Limited (AHCL) has entered into a Share Purchase Agreement to acquire a 63.98% controlling stake in Remember India Health Links Private Limited for a cash consideration of ₹5.38 crore. This acquisition is a strategic move to transition AHCL from an API manufacturer to a complete pharmaceutical provider with Finished Dosage Formulations (FDF) capabilities. The deal provides AHCL access to over 30 product dossiers and facilitates entry into retail and hospital markets. While the target company's turnover declined to ₹83.08 lakh in FY25 from ₹169.83 lakh in FY24, the acquisition is expected to strengthen AHCL's long-term financial and regulatory profile.
Key Highlights
Acquisition of 1,11,00,000 equity shares representing 63.98% shareholding and management control.
Total acquisition cost of ₹5,38,12,800 at a price of ₹4.848 per share.
Strategic expansion from API manufacturing into Finished Dosage Formulations (FDF) with 30+ dossiers.
Target company turnover history: ₹83.08 lakh (FY25), ₹169.83 lakh (FY24), and ₹98.65 lakh (FY23).
Expected completion of the transaction within 4 to 5 months from the date of signing.
👀 What to Watch
Investors should view this as a positive vertical integration move that expands AHCL's addressable market, though they should monitor the company's ability to scale the target's currently small revenue base.
Anlon Healthcare to Acquire 63.98% Stake in Remember India Health Links for ₹5.38 Crore
Anlon Healthcare (AHCL) has approved the acquisition of a 63.98% majority stake in Remember India Health Links Private Limited for a cash consideration of ₹5.38 crore. This strategic move is designed to transition AHCL from an API manufacturer to a complete pharmaceutical provider by entering the Finished Dosage Formulations (FDF) segment. The acquisition provides AHCL with access to over 30 product dossiers and is expected to be completed within 4-5 months. While the target's FY25 turnover was modest at ₹83.08 lakh, the deal facilitates AHCL's entry into retail and hospital markets.
Key Highlights
Acquisition of 1,11,00,000 equity shares representing a 63.98% controlling stake.
Total cash consideration of ₹5,38,12,800 at an acquisition price of ₹4.848 per share.
Strategic shift from API manufacturing to Finished Dosage Formulations (FDF) with access to 30+ dossiers.
Target company turnover for FY25 was ₹83.08 lakh, showing a decline from ₹169.83 lakh in FY24.
The transaction is expected to be completed within a timeline of 4 to 5 months.
👀 What to Watch
Investors should monitor the successful integration of the FDF business and how AHCL leverages the new dossiers to reverse the target company's declining revenue trend.
Anlon Healthcare: Credit Rating Upgraded to BB+/Stable and Withdrawn Following Debt Closure
Anlon Healthcare Limited (AHCL) has announced that Brickwork Ratings has upgraded its credit rating from 'BWR C' (Issuer Not Cooperating) to 'BWR BB+/Stable' before subsequently withdrawing it at the company's request. The withdrawal pertains to bank loan facilities totaling ₹24.50 Crores and includes the closure of term loans worth ₹10.36 Crores. The company has successfully obtained a No Objection Certificate (NOC) and closure letter from Punjab National Bank for the repaid facilities. This transition indicates improved financial transparency and a reduction in long-term debt obligations.
Key Highlights
Credit rating upgraded from 'Issuer Not Cooperating' (BWR C) to 'BWR BB+/Stable' prior to withdrawal.
Withdrawal of ratings for bank loan facilities aggregating to ₹24.50 Crores.
Successful closure and withdrawal of term loans amounting to ₹10.36 Crores.
Obtained No Objection Certificate (NOC) from Punjab National Bank for the closed loan facilities.
👀 What to Watch
The upgrade from a non-cooperative status and the closure of term loans are positive indicators of improving financial health and debt management. Investors should view this as a sign of operational stabilization, though they should monitor future funding requirements.
Anlon Healthcare Approves 1:5 Stock Split and Doubles Authorized Capital to Rs. 110 Crore
Anlon Healthcare Limited has received shareholder approval to sub-divide its equity shares, reducing the face value from Rs. 10 to Rs. 2 per share. Additionally, the company has doubled its Authorized Share Capital from Rs. 55 crore to Rs. 110 crore. These changes were approved via a Special Resolution through a Postal Ballot on April 08, 2026. The move is designed to enhance market liquidity and provide the company with the flexibility to raise capital in the future.
Key Highlights
Approved sub-division of equity shares from face value of Rs. 10 to Rs. 2 each (1:5 split ratio)
Increased Authorized Share Capital from Rs. 55,00,00,000 to Rs. 1,10,00,00,000
Total authorized equity shares increased from 5.5 crore to 55 crore shares of Rs. 2 each
Amendments to the Capital Clause (Clause V) of the Memorandum of Association (MOA) ratified by shareholders
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding the record date for the stock split, which is expected to improve retail participation. The significant increase in authorized capital suggests the management may be planning future equity fundraises or inorganic growth opportunities.
Anlon Healthcare Sets April 24 Record Date for 1:5 Stock Split and 1:1 Bonus Issue
Anlon Healthcare Limited (AHCL) has fixed April 24, 2026, as the record date for a dual corporate action involving a stock split and a bonus issue. The company will first subdivide its equity shares from a face value of Rs. 10 to Rs. 2 (1:5 ratio). Subsequently, it will issue bonus shares in a 1:1 ratio based on the new face value. This combined action will result in shareholders receiving 10 shares for every 1 share currently held, though the market price will adjust proportionally.
Key Highlights
Record date for both stock split and bonus issue is fixed for April 24, 2026.
Stock split ratio of 1:5 will reduce face value from Rs. 10 to Rs. 2 per share.
Bonus issue ratio of 1:1 will be applied to the post-split shares.
The total number of shares held by an investor will increase by a factor of 10.
Corporate action aims to improve stock liquidity and retail participation.
👀 What to Watch
Investors looking to benefit from the split and bonus should ensure they own the shares before the ex-date. Existing shareholders do not need to take any action as the additional shares will be credited automatically to their demat accounts.
Anlon Healthcare Shareholders Approve 1:5 Stock Split and Bonus Issue
Anlon Healthcare Limited (AHCL) has received shareholder approval via postal ballot for a significant capital restructuring. Key resolutions passed include a 1:5 stock split, where each share of face value Rs. 10 will be subdivided into five shares of Rs. 2 each, and the issuance of bonus shares. The resolutions were passed with near-unanimous support, with over 99.99% of polled votes in favor of the proposals.
Key Highlights
Approved sub-division of equity shares from a face value of Rs. 10 to Rs. 2 per share (1:5 split).
Shareholders ratified the issuance of Bonus Shares to eligible members.
Increase in Authorized Share Capital and subsequent alteration of the Memorandum of Association approved.
Total of 31,097,233 votes were polled, representing approximately 58.51% of the total paid-up equity capital.
All five resolutions passed with more than 99.99% of votes cast in favor.
👀 What to Watch
Investors should monitor the company's upcoming announcements for the 'Record Date' to qualify for the stock split and bonus shares. These corporate actions are likely to increase the liquidity of the stock and make it more accessible to retail investors.
Anlon Healthcare Completes Acquisition of 56.67% Stake in Bizotic Life Science
Anlon Healthcare Limited (AHCL) has officially completed the acquisition of a 56.67% equity stake in Bizotic Life Science Private Limited as of March 20, 2026. This follows a Share Purchase Agreement (SPA) initiated in November 2025 and a subsequent extension granted in February 2026. With the completion of this transaction, Bizotic Life Science has now become a subsidiary of AHCL. The acquisition was finalized well within the extended deadline of April 2, 2026, marking a significant step in AHCL's expansion strategy.
Key Highlights
Successfully acquired a controlling 56.67% equity shareholding in Bizotic Life Science Private Limited.
Bizotic Life Science Private Limited has officially become a subsidiary of Anlon Healthcare Limited.
Transaction completed on March 20, 2026, ahead of the April 2, 2026 extension deadline.
The acquisition follows the original Share Purchase Agreement dated November 28, 2025.
👀 What to Watch
Investors should view this as a positive growth move and monitor upcoming quarterly results to assess the financial contribution of the new subsidiary. Watch for further management commentary on synergy benefits and integration timelines.
Anlon Healthcare Announces 1:5 Stock Split; Face Value to Drop from ₹10 to ₹2
Anlon Healthcare Limited (AHCL) has initiated a postal ballot to seek shareholder approval for a 1:5 stock split. Under this proposal, each equity share with a face value of ₹10 will be sub-divided into five equity shares with a face value of ₹2 each. The total authorized share capital will remain unchanged at ₹55 crore, while the number of shares will increase to 27.5 crore. The e-voting process for shareholders is scheduled to take place between March 10 and April 08, 2026.
Key Highlights
Sub-division of 1 equity share of ₹10 face value into 5 equity shares of ₹2 face value
Total paid-up shares to increase from 5,31,51,500 to 26,57,57,500 post-split
Authorized share capital remains constant at ₹55,00,00,000
Remote e-voting period is set from March 10, 2026, to April 08, 2026
The split is intended to enhance liquidity and make shares more affordable for retail investors
👀 What to Watch
Investors should monitor the record date for the split, which will be announced after shareholder approval. While the split increases the number of shares held, it does not change the fundamental value of the investment but may improve market liquidity.
Anlon Healthcare Approves 1:5 Stock Split and 1:1 Bonus Issue
Anlon Healthcare Limited has announced a significant restructuring of its share capital, starting with a 1:5 stock split that reduces the face value from Rs. 10 to Rs. 2. Following the split, the company will issue bonus shares in a 1:1 ratio to all eligible shareholders. To accommodate these changes, the authorized share capital is being doubled from Rs. 55 crore to Rs. 110 crore. These corporate actions are intended to enhance market liquidity and encourage wider participation from retail investors.
Key Highlights
Stock split of 1 equity share (FV Rs. 10) into 5 equity shares (FV Rs. 2) to improve liquidity
Bonus issue in the ratio of 1:1 (one new share for every one held) post-split adjustment
Authorized share capital increased from Rs. 55 crore to Rs. 110 crore to facilitate the issuance
Company has Rs. 147.08 crore in free reserves as of Dec 31, 2025, to support the Rs. 53.15 crore bonus capitalization
Expected completion of both corporate actions is within 2 months, by May 6, 2026
👀 What to Watch
Investors should monitor the upcoming record date to be eligible for both the split and bonus shares. While these actions do not change the company's fundamentals, the increased liquidity and lower nominal price per share often attract higher retail trading volume.
Anlon Healthcare Announces 1:5 Stock Split and 1:1 Bonus Issue
Anlon Healthcare's Board has approved a stock split where each share of face value Rs. 10 will be divided into 5 shares of Rs. 2 each. Following this split, the company will issue bonus shares in a 1:1 ratio, effectively resulting in 10 shares for every 1 share held currently. To facilitate these actions, the authorized share capital is being doubled from Rs. 55 crore to Rs. 110 crore. The bonus issue will capitalize Rs. 53.15 crore from the company's free reserves, which stood at Rs. 147.08 crore as of December 2025.
Key Highlights
Stock split ratio of 1:5, reducing face value from Rs. 10 to Rs. 2 per share
Bonus issue approved in the ratio of 1:1 on the post-split face value
Authorized share capital increased from Rs. 55 crore to Rs. 110 crore
Paid-up capital to increase from Rs. 53.15 crore to Rs. 106.30 crore post-bonus
Corporate actions expected to be completed by May 6, 2026, subject to shareholder approval
👀 What to Watch
Investors should monitor the upcoming record date to be eligible for the split and bonus shares. While these actions improve liquidity and affordability, they do not change the underlying fundamentals of the company.
Anlon Healthcare Extends Timeline for 56.67% Stake Acquisition in Bizotic Life Science
Anlon Healthcare Limited (AHCL) has announced an amendment to its Share Purchase Agreement (SPA) for the acquisition of a 56.67% stake in Bizotic Life Science Private Limited. The completion timeline for the transaction has been extended to April 2, 2026, which is 125 days from the original execution date of November 28, 2025. The company cited pending procedural requirements as the reason for this extension. This delay indicates that while the deal is still active, the final integration and control of the target company will take longer than initially anticipated.
Key Highlights
Acquisition involves a controlling 56.67% stake in Bizotic Life Science Private Limited.
Completion deadline extended to April 2, 2026, from the original schedule.
The new timeline allows for 125 days from the initial SPA date of November 28, 2025.
Extension is attributed to procedural requirements rather than financial or legal hurdles.
👀 What to Watch
Investors should monitor the company's progress toward the new April 2 deadline to ensure the acquisition is finalized without further delays. The successful completion of this majority stake purchase is critical for AHCL's expansion plans.
Anlon Healthcare Q3 FY26 PAT at ₹5.15 Cr; Targets ₹380 Cr Revenue in FY27
Anlon Healthcare (AHCL) reported a strong Q3 FY26 with total income rising to ₹35.78 crore from ₹9.38 crore YoY, and a PAT of ₹5.15 crore. The company has provided an ambitious revenue guidance of ₹370-380 crore for FY27, driven by the integration of Apiqo Organic and the proposed acquisition of Bizotic Life Science. Management maintains a sustainable EBITDA margin target of 35% for domestic and 50% for regulated markets. A key focus remains on optimizing the balance sheet by reducing working capital days from 290 to 150-160 days by FY27.
Key Highlights
Q3 FY26 revenue surged to ₹35.78 crore vs ₹9.38 crore YoY, with EBITDA margins at 35.06%.
Management projects FY27 revenue at ₹370-380 crore, significantly higher than the FY26 guidance of ₹170-180 crore.
Total capacity across three facilities is estimated at 1,400-1,600 MTPA, with a further 800-1,000 MTPA Greenfield expansion planned.
Working capital cycle is being aggressively managed with a target to reduce receivable days from 290 to 150-160 days by next year.
CDMO segment is scaling with 3 molecules under development for global innovators, with one validation batch already dispatched.
👀 What to Watch
Investors should monitor the successful integration of recent acquisitions and the actual reduction in receivable days to confirm operational efficiency. The high growth guidance and strong margin profile suggest a positive outlook for the company's expansion into regulated markets.
